FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001267067> ?p ?o ?g. }

• W2001267067 abstract "Currently there is no curative treatment for metastatic clear cell renal cell cancer, the commonest variant of the disease. A key factor in this treatment resistance is thought to be the molecular complexity of the disease 1. Targeted therapy such as the tyrosine kinase inhibitor (TKI)-sunitinib have been utilized, but only 40% of patients will respond, with the overwhelming majority of these patients relapsing within 1 year 2. As such the question of intrinsic and acquired resistance in renal cell cancer patients is highly relevant 3. In order to study resistance to TKIs, with the ultimate goal of developing effective, personalized treatments, sequential tissue after a specific period of targeted therapy is required, an approach which had proved successful in chronic myeloid leukaemia 4. However the application of such a strategy in renal cell carcinoma is complicated by the high level of both inter- and intratumoral heterogeneity, which is a feature of renal cell carcinoma5,6 as well as other solid tumors 7. Intertumoral heterogeneity due to transcriptomic and genetic differences is well established even in patients with similar presentation, stage and grade of tumor. In addition it is clear that there is great morphological (intratumoral) heterogeneity in RCC, which is likely to represent even greater molecular heterogeneity. Detailed mapping and categorization of RCC tumors by combined morphological analysis and Fuhrman grading allows the selection of representative areas for proteomic analysis. Protein based analysis of RCC8 is attractive due to its widespread availability in pathology laboratories; however, its application can be problematic due to the limited availability of specific antibodies 9. Due to the dot blot nature of the Reverse Phase Protein Arrays (RPPA), antibody specificity must be pre-validated; as such strict quality control of antibodies used is of paramount importance. Despite this limitation the dot blot format does allow assay miniaturization, allowing for the printing of hundreds of samples onto a single nitrocellulose slide. Printed slides can then be analyzed in a similar fashion to Western analysis with the use of target specific primary antibodies and fluorescently labelled secondary antibodies, allowing for multiplexing. Differential protein expression across all the samples on a slide can then be analyzed simultaneously by comparing the relative level of fluorescence in a more cost-effective and high-throughput manner." @default.
• W2001267067 created "2016-06-24" @default.
• W2001267067 creator A5008143523 @default.
• W2001267067 creator A5009340780 @default.
• W2001267067 creator A5012350676 @default.
• W2001267067 creator A5012800133 @default.
• W2001267067 creator A5039444207 @default.
• W2001267067 creator A5069451283 @default.
• W2001267067 creator A5069566006 @default.
• W2001267067 creator A5073294850 @default.
• W2001267067 creator A5076006917 @default.
• W2001267067 creator A5079174204 @default.
• W2001267067 creator A5087379820 @default.
• W2001267067 creator A5089893713 @default.
• W2001267067 date "2013-01-22" @default.
• W2001267067 modified "2023-10-01" @default.
• W2001267067 title "The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers" @default.
• W2001267067 cites W2050163394 @default.
• W2001267067 cites W2053251145 @default.
• W2001267067 cites W2068123273 @default.
• W2001267067 cites W2082394458 @default.
• W2001267067 cites W2083353096 @default.
• W2001267067 cites W2110065044 @default.
• W2001267067 cites W2134977016 @default.
• W2001267067 cites W2136927373 @default.
• W2001267067 cites W2150575159 @default.
• W2001267067 cites W2165086913 @default.
• W2001267067 cites W2166788033 @default.
• W2001267067 cites W2169895148 @default.
• W2001267067 doi "https://doi.org/10.3791/50221" @default.
• W2001267067 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3582682" @default.
• W2001267067 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23380956" @default.
• W2001267067 hasPublicationYear "2013" @default.
• W2001267067 type Work @default.
• W2001267067 sameAs 2001267067 @default.
• W2001267067 citedByCount "8" @default.
• W2001267067 countsByYear W20012670672014 @default.
• W2001267067 countsByYear W20012670672015 @default.
• W2001267067 countsByYear W20012670672017 @default.
• W2001267067 countsByYear W20012670672018 @default.
• W2001267067 countsByYear W20012670672019 @default.
• W2001267067 countsByYear W20012670672021 @default.
• W2001267067 crossrefType "journal-article" @default.
• W2001267067 hasAuthorship W2001267067A5008143523 @default.
• W2001267067 hasAuthorship W2001267067A5009340780 @default.
• W2001267067 hasAuthorship W2001267067A5012350676 @default.
• W2001267067 hasAuthorship W2001267067A5012800133 @default.
• W2001267067 hasAuthorship W2001267067A5039444207 @default.
• W2001267067 hasAuthorship W2001267067A5069451283 @default.
• W2001267067 hasAuthorship W2001267067A5069566006 @default.
• W2001267067 hasAuthorship W2001267067A5073294850 @default.
• W2001267067 hasAuthorship W2001267067A5076006917 @default.
• W2001267067 hasAuthorship W2001267067A5079174204 @default.
• W2001267067 hasAuthorship W2001267067A5087379820 @default.
• W2001267067 hasAuthorship W2001267067A5089893713 @default.
• W2001267067 hasBestOaLocation W20012670672 @default.
• W2001267067 hasConcept C104317684 @default.
• W2001267067 hasConcept C121608353 @default.
• W2001267067 hasConcept C126322002 @default.
• W2001267067 hasConcept C127716648 @default.
• W2001267067 hasConcept C142724271 @default.
• W2001267067 hasConcept C143998085 @default.
• W2001267067 hasConcept C18903297 @default.
• W2001267067 hasConcept C2777286243 @default.
• W2001267067 hasConcept C2777306565 @default.
• W2001267067 hasConcept C2777472916 @default.
• W2001267067 hasConcept C2778019345 @default.
• W2001267067 hasConcept C2778695046 @default.
• W2001267067 hasConcept C2779134260 @default.
• W2001267067 hasConcept C2779490328 @default.
• W2001267067 hasConcept C2781068499 @default.
• W2001267067 hasConcept C2781230642 @default.
• W2001267067 hasConcept C2781278892 @default.
• W2001267067 hasConcept C502942594 @default.
• W2001267067 hasConcept C54355233 @default.
• W2001267067 hasConcept C60644358 @default.
• W2001267067 hasConcept C64618202 @default.
• W2001267067 hasConcept C71924100 @default.
• W2001267067 hasConcept C86803240 @default.
• W2001267067 hasConceptScore W2001267067C104317684 @default.
• W2001267067 hasConceptScore W2001267067C121608353 @default.
• W2001267067 hasConceptScore W2001267067C126322002 @default.
• W2001267067 hasConceptScore W2001267067C127716648 @default.
• W2001267067 hasConceptScore W2001267067C142724271 @default.
• W2001267067 hasConceptScore W2001267067C143998085 @default.
• W2001267067 hasConceptScore W2001267067C18903297 @default.
• W2001267067 hasConceptScore W2001267067C2777286243 @default.
• W2001267067 hasConceptScore W2001267067C2777306565 @default.
• W2001267067 hasConceptScore W2001267067C2777472916 @default.
• W2001267067 hasConceptScore W2001267067C2778019345 @default.
• W2001267067 hasConceptScore W2001267067C2778695046 @default.
• W2001267067 hasConceptScore W2001267067C2779134260 @default.
• W2001267067 hasConceptScore W2001267067C2779490328 @default.
• W2001267067 hasConceptScore W2001267067C2781068499 @default.
• W2001267067 hasConceptScore W2001267067C2781230642 @default.
• W2001267067 hasConceptScore W2001267067C2781278892 @default.
• W2001267067 hasConceptScore W2001267067C502942594 @default.
• W2001267067 hasConceptScore W2001267067C54355233 @default.
• W2001267067 hasConceptScore W2001267067C60644358 @default.
• W2001267067 hasConceptScore W2001267067C64618202 @default.

• next